Merck’s HDL-Raising Cholesterol Combo Has “Formulation Issues”
This article was originally published in The Pink Sheet Daily
Executive Summary
MK-0524B Phase III studies remain on track, the company maintains.
You may also be interested in...
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
Merck Ends Development Of Phase II Artherosclerosis Candidate
Two Phase III candidates, however, could be potential successors to Zocor.